Stockreport

Exelixis Needs To Move Away From Its Overdependence On Cabozantinib [Seeking Alpha]

Exelixis, Inc.  (EXEL) 
Last exelixis, inc. earnings: 2/25 04:05 pm Check Earnings Report
PDF FatCamera/E+ via Getty ImagesThe trouble with Exelixis (NASDAQ:EXELgeneric polymorph version of cabo. That means, despite cabo being a $1+bn blockbuster drug, the compan [Read more]